Guizhou Sanli Pharmaceutical Co Ltd (603439) — Cash Flow-to-Debt Ratio
Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.19 Million could theoretically repay 0% of its total liabilities (CN¥1.30 Billion) in one year. See Guizhou Sanli Pharmaceutical Co Ltd (603439) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Sanli Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Guizhou Sanli Pharmaceutical Co Ltd across 12 annual periods. Also explore net asset growth rate of Guizhou Sanli Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Guizhou Sanli Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Guizhou Sanli Pharmaceutical Co Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | CN¥107.07 Million | CN¥1.60 Billion | ▼ -70.7% |
| 2023 | 0.23x | CN¥276.70 Million | CN¥1.21 Billion | ▼ -54.9% |
| 2022 | 0.51x | CN¥293.29 Million | CN¥578.40 Million | ▲ +22.0% |
| 2021 | 0.42x | CN¥155.04 Million | CN¥372.93 Million | ▲ +82.0% |
| 2020 | 0.23x | CN¥63.25 Million | CN¥276.91 Million | ▼ -84.3% |
| 2019 | 1.46x | CN¥116.24 Million | CN¥79.72 Million | ▲ +13.6% |
| 2018 | 1.28x | CN¥75.35 Million | CN¥58.69 Million | ▲ +105.7% |
| 2017 | 0.62x | CN¥57.47 Million | CN¥92.07 Million | ▲ +55.5% |
| 2016 | 0.40x | CN¥35.10 Million | CN¥87.44 Million | ▲ +3.9% |
| 2015 | 0.39x | CN¥33.28 Million | CN¥86.14 Million | ▲ +9476.2% |
| 2014 | 0.00x | CN¥563.46K | CN¥139.67 Million | ▼ -98.2% |
| 2013 | 0.23x | CN¥30.09 Million | CN¥130.52 Million | — |